Voyageur Pharmaceuticals Ltd (TSX-V:VM, OTC:VYYRF) CEO Brent Willis takes Proactive's Stephen Gunnion through the company's plan to develop new commercial fullerene-based contrast agents for use in medical imaging together with Rain Cage Carbon Inc (RCC).
Willis says RCC will be a source of a high quality fullerenes for its radiology contrast media drug pipeline, using Voyageur's sources of iodine and barium.
With that, Voyageur is on track to become one of the first carbon-neutral pharmaceutical company in the world, he adds.
#ProactiveInvestors #VoyageurPharmaceuticals #RainCageCarbon #fullerene #TSX #OTC